Under construction – not a live service
Sign in
Taking people in ChinaNo phase

A New PET Scan Tracer Targeting CDH3 in Lung Tumors

Tests a CDH3-targeted PET scan for imaging lung tumors in adults.

Key facts

Who runs it
Peking University People's Hospital
Where
Beijing, ChinaSee the site
Trial code
Registry title
Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors
Status
Recruiting
People taking part
80 people, planned
Started
18 Mar 2026
Expected to end
30 Jul 2027
Type of study
Observational
Treatments tested
  • PET/CT scans
Record updated
2 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a suspected or confirmed lung cancer who have not yet had cancer treatment. They will have a PET scan with a new probe, 68Ga-TOI-1, that targets CDH3.

Age
18 years or older
Sex
Men and women can join.
Disease stage
Lung cancer confirmed by biopsy, or lung nodules highly suspected to be malignant. Able to have surgery or a biopsy to get a pathology diagnosis.
Earlier treatment
No radiotherapy or chemotherapy before. No other anti-tumor treatment before.

Main reasons for not taking part

  • Pregnant, planning pregnancy, or breastfeeding
  • History of another cancer
  • Fear of closed spaces or another mental illness
  • Poor or missing PET scan image quality
  • Blood, liver or kidney tests outside the limits set in the record

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Age ≥ 18 years, male or female, with an ECOG performance status of 0 or 1
  • Availability of complete clinical and imaging data
  • Life expectancy ≥ 12 weeks
  • Hematology, liver and kidney function meeting the following criteria: Hematology: WBC ≥ 4.0 × 10⁹/L or neutrophils ≥ 1.5 × 10⁹/L, PLT ≥ 100 × 10⁹/L, Hb ≥ 90 g/L; PT or APTT ≤ 1.5 × ULN; Liver and kidney function: T-Bil ≤ 1.5 × ULN, ALT/AST ≤ 2.5 × ULN, ALP ≤ 2.5 × ULN; BUN ≤ 1.5 × ULN, SCr ≤ 1.5 × ULN
  • Patients who have not received radiotherapy or chemotherapy and are eligible for surgical resection or biopsy to obtain a pathological diagnosis, or those highly suspected of having malignant pulmonary nodules according to clinical diagnostic criteria
  • Pathologically confirmed lung cancer via biopsy before neoadjuvant therapy; life expectancy ≥ 12 weeks
  • Ability to provide adequate tumor tissue for testing and research

Who cannot take part

  • History of other malignant tumors or prior receipt of other anti-tumor therapies
  • Presence of claustrophobia or other mental illnesses
  • Any other conditions deemed by the investigators as inappropriate for participation in this study
  • Women who are planning pregnancy, pregnant, or breastfeeding
  • Poor or missing PET scan image quality of the probe that fails to meet analysis standards

Where in China

  • Peking University People's HospitalBeijing, ChinaContact: Kezhong Chen, MDTaking people

About the trial

What the trial wants to find out

Lung malignant tumors are a significant health threat with high incidence and mortality rates, and molecular imaging is crucial for early diagnosis, staging, prognosis evaluation, and therapeutic efficacy assessment. 18F-FDG PET imaging is widely used, but has limitations. CDH3 is a promising target for tumor-targeted imaging, as it is only expressed in cancerous epithelial cells. A new PET probe, 68Ga-TOI-1, targeting CDH3 has been developed with better affinity and selectivity than previous probes. Preclinical data support its safety and metabolic stability, and future research will explore its diagnostic and staging value in different types of lung tumors, providing a new and precise evaluation method for lung malignant tumors.

The group in the trial

  • CDH3-targeted PET in lung malignant tumors

    Participant who conforms to the inclusion criteria will undergo 18F-FDG and 68Ga-CDH3 PET/CT scans within 1 week.

    Treatment: PET/CT scans

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Single-arm, Open-label, Single-center Clinical Study to Evaluate CDH3-targeted Positron Emission Tomography (PET) for Lung Malignant Tumors
Plain-language title
A New PET Scan Tracer Targeting CDH3 in Lung TumorsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
2 April 2026